Jefferies (NYSE:JEF) analyst Michael Yee maintained a Hold rating on Moderna (NASDAQ:MRNA) on Thursday, setting a price target of $485, which is approximately 46.14% above the present share price of $331.88.
Yee expects Moderna to post earnings per share (EPS) of $6.93 for the fourth quarter of 2021.
The current consensus among 12 TipRanks analysts is for a Hold rating of shares in Moderna, with an average price target of $363.13.
The analysts price targets range from a high of $485 to a low of $115.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $4.35 billion and a net profit of $3.06 billion. The company's market cap is $133.96 billion.
According to TipRanks.com, Jefferies analyst Michael Yee is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.8% and a 45.63% success rate.
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.